DPP4 and diabetes mellitus: Kishima et al. conducted a prospective RCT to compare the suppressive effects of tofogliflozin and anagliptin, a DPP-4 inhibitor, on atrial fibrillation recurrence after catheter ablation in patients with type 2 diabetes mellitus.